Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025

Page 7 of 14

8. Akero Therapeutics Inc (NASDAQ:AKRO)

Number of Hedge Fund Holders In Q3 2024: 30

Akero Therapeutics Inc (NASDAQ:AKRO) is a biotech company that makes treatments for metabolic diseases.

The stock has delivered stellar gains so far in 2025 as 39% of patients receiving its drug achieved ≥1 stage improvement in liver fibrosis without worsening of MASH at 96 weeks. This is compared to 15% for placebo.

The results were consistent across both completer analysis and intent-to-treat (ITT) analysis.

The drug seems to have a good safety profile with no deaths in the EFX group and manageable gastrointestinal side effects. This could be a first-in-class therapy for MASH-induced cirrhosis.

It completed an upsized public offering in January and raised $402.5 million by selling 6.4 million shares at $48 each.

The consensus price target of $75.86 implies 41.04% upside.

AKRO stock is up 94.03% year-to-date.

Page 7 of 14